Cost-effectiveness of Xpert®MTB/RIF in the diagnosis of tuberculosis: pragmatic study.

Suely Conceição Alves da SilvaMaria Claudia VaterDaniela Maria de Paula RamalhoIsabela Neves de AlmeidaSilvana Spindola de MirandaAfrânio Kritski

Published in: Revista da Sociedade Brasileira de Medicina Tropical (2021)

The Xpert in the diagnosis of TB-DR in these reference units was cost-effective with subsidies. In the absence of a subsidy, Xpert in TB-DR is not characterized as cost effective. This factor reveals the vulnerability of countries dependent on international organizations' subsidy policies.

Keyphrases

mycobacterium tuberculosis
pulmonary tuberculosis
editorial comment
public health
climate change
study protocol
hepatitis c virus